Rationale for Assessing Tobacco Use in Cancer Clinical Trials
• To improve evaluations of new cancer therapies by adjusting for tobacco use in analyses. This is critical because tobacco use can diminish treatment efficacy, increase treatment toxicity, and adversely affect clinical outcomes.
• To address scientific questions regarding tobacco use by cancer patients, for example: -How and when does tobacco diminish treatment efficacy? -What are the mechanisms of tobacco effects? -How much improvement occurs in prognosis when patients stop using tobacco after a cancer diagnosis?
About the NCI-AACR Cancer Patient Tobacco Use Assessment Task Force
The Task Force was established in 2013 to develop patient-reported tobacco use measures that are tailored to the trajectory of cancer diagnosis, treatment, and survivorship; recommended timing of assessments; and a research agenda regarding tobacco use by cancer patients.
Task Force Recommendations
• Timing of tobacco use assessment in clinical trials -At a minimum: at registration and at end of protocol therapy -Recommended: § immediately before and after cancer surgery § monthly or at key points during therapy ◊ day 1 of each chemotherapy cycle ◊ beginning and end of radiation therapy ◊ beginning and end of other systemic therapy § 6-12 months after the end of cancer therapy • Broad, systematic inclusion of tobacco use assessment in cancer research • Research priorities: detailed in publications
